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Objectives: Daptomycin was tested in vitro and in rats with experimental endocarditis against the
ampicillin-susceptible and vancomycin-susceptible Enterococcus faecalis JH2-2, the vancomycin-
resistant (VanA type) mutant of strain JH2-2 (strain JH2-2/pIP819), and the ampicillin-resistant and
vancomycin-resistant (VanB type) Enterococcus faecium D366.
Methods: Rats with catheter-induced aortic vegetations were treated with doses simulating intra-
venously kinetics in humans of daptomycin (6 mg/kg every 24 h), amoxicillin (2 g every 6 h), vancomycin
(1 g every 12 h) or teicoplanin (12 mg/kg every 12 h). Treatment was started 16 h post-inoculation and
continued for 2 days.
Results: MICs of daptomycin were 1, 1 and 2 mg/L, respectively, for strains JH2-2, JH2-2/pIP819 and
D366. In time–kill studies, daptomycin showed rapid (within 2 h) bactericidal activity against all strains.
Daptomycin was highly bound to rat serum proteins (89%). In the presence of 50% rat serum, simulating
free concentrations, daptomycin killing was maintained but delayed (6–24 h). In vivo, daptomycin
treatment resulted in 10 of 12 (83%), 9 of 11 (82%) and 11 of 12 (91%) culture-negative vegetations in rats
infected with strains JH2-2, JH2-2/pIP819 and D366, respectively (P < 0.001 compared to controls).
Daptomycin efficacy was comparable to that of amoxicillin and vancomycin for susceptible isolates.
Daptomycin, however, was significantly (P < 0.05) more effective than teicoplanin against the
glycopeptide-susceptible strain JH2-2 and superior to all comparators against resistant isolates.
Conclusions: These results support the use of the newly proposed daptomycin dose of 6 mg/kg every
24 h for treatment of enterococcal infections in humans.
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Introduction
Enterococci have become the third major leading cause of
nosocomial bacteraemia, an infection which is significantly
associated with the risk of developing infective endocarditis.1,2
The enterococci pose a considerable therapeutic problem since
they display resistance to a wide range of antimicrobial agents
including aminoglycosides, penicillins and glycopeptides.3,4 In
particular, Enterococcus faecalis are frequently highly resistant
to aminoglycosides5 although resistance to ampicillin and glyco-
peptides is still rare.1,5 In contrast, Enterococcus faecium are
frequently highly resistant to aminoglycosides, ampicillin and
glycopeptides.5 Moreover, some of these isolates showed limited
susceptibility to many other agents.5
The problematic treatment of enterococcal infections empha-
sizes the need for evaluation of new effective therapeutic options.
New antimicrobial agents, such as quinupristin/dalfopristin and
linezolid, have recently become available as therapeutic alternatives
for infections due to multidrug-resistant Gram-positive bacteria,
but their activity against enterococci is mainly bacteriostatic.6
Daptomycin is a new cyclic lipopeptide antibiotic that shows
rapid concentration-dependent bactericidal activity in vitro against
a wide range of resistant Gram-positive organisms, including
ampicillin-resistant and vancomycin-resistant enterococci.7–10
Daptomycin is also active against enterococcal isolates resistant
to quinupristin-dalfopristin and linezolid.10 Thus, its activity does
not seem to be affected by mechanisms of resistance to other
classes of drugs. In addition, daptomycin showed low potential for
in vitro spontaneous acquisition of antibiotic resistance.11 This
reflects the unique mode of its antibacterial action, which involves
the disruption of the bacterial membrane potential without
penetration into the cytoplasm.7,8
Animal studies conducted in the nineties have shown limited
activity of daptomycin against experimental E. faecalis and
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E. faecium endocarditis despite the good in vitro bactericidal
activity of the drug.12,13 However, those studies used doses of
daptomycin in an attempt to reproduce peak levels in human
serum of a 3–4 mg/kg every 12 h regimen.14 The lack of efficacy
of such low-dose treatments was attributed to the high level of
protein binding of daptomycin in serum, that likely resulted in
inadequate unbound concentrations of the drug.12,13 A new
intravenous daptomycin dose regimen of 6 mg/kg once daily is
now proposed for subjects with infections due to resistant Gram-
positive bacteria.8,15 Administration of 6 mg/kg of daptomycin
once daily resulted both in higher peak (Cmax) serum drug levels
and more favourable area under the concentration–time curve
(AUC) over the MIC for the infecting organism (Cmax/MIC ratio
and AUC/MIC ratio, respectively), the pharmacodynamic para-
meters that best predict outcome with daptomycin.16,17 Moreover,
single daily administration demonstrated a low probability of
accumulation-related adverse effects compared to multiple dose
regimens.18 The purpose of the present study was to evaluate
daptomycin, at doses simulating kinetics in humans of 6 mg/kg
once daily, in rats with experimental endocarditis due to either
E. faecalis or E. faecium. The endocarditis model is particularly
stringent for antibiotic efficacy, because the infected vegetation is
an area that does not allow the natural host defences to operate
optimally19 and the killing of bacteria depends on the intrinsic
potential of the drug. The efficacy of daptomycin was compared
with that of amoxicillin, vancomycin and teicoplanin.
Materials and methods
Microorganisms and growth conditions
The E. faecalis JH2-2 isolate, which is susceptible to ampicillin and
to vancomycin,20 its vancomycin-resistant (VanA type) trans-
conjugant mutant E. faecalis JH2-2/pIP819 and the clinical isolate
E. faecium D366, which is ampicillin resistant and vancomycin
resistant (VanB type),21 were used. E. faecalis JH2-2 and JH2-2/
pIP819 were kindly provided by R. Leclercq (Coˆte de Nacre Hospital,
Caen, France) and E. faecium D366 by J. L. Mainardi, (Georges
Pompidou Hospital, Paris, France). Bacteria were grown without
shaking at 37C in brain heart infusion (BHI) broth (Difco
Laboratories, Detroit, MI, USA) Colony counts were determined
using tryptic soy agar (TSA; Difco) plates.
Antibiotics
Daptomycin was kindly supplied by Chiron Biopharmaceuticals
(Uxbridge, UK). Amoxicillin was purchased from GlaxoSmithKline
(Mu¨nchenbuchsee, Switzerland), vancomycin from Eli Lilly
(Vernier/Gene`ve, Switzerland) and teicoplanin from Aventis Pharma
(Zu¨rich, Switzerland).
In vitro susceptibility studies
MICs of the test drugs were determined by the broth microdilution
method according to CLSI recommendations22 in cation-adjusted
Mueller–Hinton broth (MHB, Difco Laboratories, Detroit, MI, USA)
with an inoculum of 5 · 105–1 · 106 cfu/mL from an overnight
culture. When testing daptomycin, MHB was supplemented with
50 mg/L Ca2+.9 MIC was defined as the lowest concentration
of antibiotic that completely inhibits visible growth after 24 h of
incubation at 37C.
Time–kill studies were done in flasks with cation-adjusted MHB
alone and in flasks containing daptomycin (85 mg/L), amoxicillin
(100 mg/L), vancomycin (40 mg/L) or teicoplanin (40 mg/L).
Antibiotic concentrations were chosen to mimic peak levels of the
drugs in human serum. Flasks prewarmed at 37C were inoculated
with a final concentration of 106 cfu/mL from an overnight culture
and then incubated in a water bath at 37C without aeration. In order
to make the comparison with high bacterial densities present in
vegetations more relevant, killing curves of daptomycin were also
determined by using an inoculum of 108 cfu/mL. To evaluate the
impact of rat proteins on the bactericidal activity of daptomycin and
the comparative drugs, killing curves were also determined in MHB
supplemented with 50% rat serum alone or containing the same final
concentrations of each drug given above. Samples (0.5 mL) were
removed at 0, 2, 6, 12 and 24 h of incubation, centrifuged for 10 min
at 3000 rpm, resuspended in saline, serially diluted, plated on TSA
plates and further incubated for 48 h at 37C to determine the
number of viable bacteria. This process minimized potential anti-
biotic carryover. Bactericidal activity was defined by a decrease of
3 log10 cfu/mL after 24 h of incubation. The lower limit of detection
was 1 log10 cfu/mL. Each time–kill experiment was performed in two
to three independent occasions.
Production and treatment of experimental endocarditis
All animal experiments were carried out according to Swiss federal
and cantonal regulations. The production of catheter-induced aortic
vegetations in female Wistar rats (180–200 g) and the installation of
the programmable infusion-pump device for the delivery of the
antibiotics were performed as described previously.23,24 At 24 h after
catheterization, rats were intravenously (iv) inoculated with 0.5 mL of
saline containing 106 cfu (E. faecalis JH2-2 and E. faecalis JH2-2/
pIP819) or 107 cfu (E. faecium D366) log-phase bacteria. This
inoculum was 10 times larger than the minimum inoculum that
produces endocarditis in 90–100% of untreated rats. Treatment was
started 16 h after bacterial challenge and was administered for 2 days.
Antibiotics were delivered at changing flow rates, via the infusion
pump, at doses that simulated in rats the human kinetics of either
6 mg/kg daptomycin given iv every 24 h,14 2 g of amoxicillin given iv
every 6 h,25 1 g of vancomycin given iv every 12 h26 or 12 mg of
teicoplanin/kg iv every 12 h.27 This required total drug amounts (in
mg per kg of body weight) of 45.3 mg of daptomycin every 24 h,
130.5 mg of amoxicillin every 6 h, 68.5 mg of vancomycin over a
period of 12 h and 12.3 mg of teicoplanin over a period of 12 h. Each
experiment included a control group of untreated animals.
Pharmacokinetic studies and determination of daptomycin
protein binding
The concentrations of the antibiotic in the serum of rats were
determined by an agar diffusion assay with antibiotic medium 1
(Difco) by using Micrococcus luteus ATCC 9341 as the indicator
organism for daptomycin and Bacillus subtilis ATCC 6633 as the
indicator organism for amoxicillin, vancomycin and teicoplanin.
Standard curves were determined using pooled rat serum. The limits
of detection of the assays were 0.7 mg/L for daptomycin, 0.4 mg/L
for amoxicillin, 0.7 mg/L for vancomycin and 1.5 mg/L for
teicoplanin. The linearities of the standard curves were assessed
with a regression coefficient of 0.995, and intra-plate and inter-plate
variations were 10%. The AUC was calculated by the trapezoidal
summation method.
The binding of daptomycin to proteins in rat serum was measured
with the ultrafiltration centrifugation method28 with a daptomycin
concentration of 200 mg/L. Antibiotic concentrations were deter-
mined by bioassay as described above. The protein binding studies
were performed on three independent occasions.
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Evaluation of infection and detection of resistance in vivo
In each experiment, control rats were killed at the onset of treatment,
in order to determine the degree of valvular infection. Treated rats
were sacrificed 8 h after the trough level of the last antibiotic dose.
Aortic vegetations were removed, weighed, homogenized in 1 mL of
saline and subcultured quantitatively on TSA plates. This process
reduced potential concentrations of antimicrobial agents, which could
be carried over to the surface of an agar plate. Plates were incubated
for 48 h at 37C to determine the number of viable organisms
remaining in the vegetations. The lower limit of detection of growth
was 2 log10 cfu/g of vegetation, a value which was assigned to
cultures from which no growth was obtained.
To assess the development of daptomycin resistance in vivo,
0.1 mL samples from each vegetation homogenate were plated directly
onto TSA plates containing 4 mg/L of daptomycin (2- or 4-fold the
MIC of the drug for the test organisms). In addition, drug MICs were
routinely performed on bacteria recovered from the vegetations of
treated rats remaining infected, and results compared to the MIC for
the bacteria contained in the inoculum used for challenge.
Statistical evaluation
The incidences of valve infection of the various groups were
compared by Fisher’s exact test. The bacterial counts in vegetations
in the various groups were compared by the one-way analysis of
variance. Bonferroni correction for multiple comparison groups was
applied. Differences were considered significant when P was <0.05
by use of two-tailed significance levels.
Results
In vitro susceptibility studies
MICs are given in Table 1. All three enterococcal strains tested
were susceptible to daptomycin despite resistance to vancomycin
and teicoplanin (VanA type) in E. faecalis JH2-2/pIP819 and
to ampicillin and vancomycin (VanB type) in E. faecium 366.
The bactericidal activity of daptomycin (85 mg/L) was
tested by time–kill studies at moderate (106 cfu/mL) and high
(108 cfu/mL) inocula. As depicted in Figure 1, at both inocula
daptomycin achieved a rapid reduction in bacterial densities
(approximately a 5 log10 cfu/mL killing) by 2 h and sustained it
for a 24 h period against all tested enterococcal isolates. In
presence of 50% rat serum, the bactericidal activity of daptomycin
was unaltered but was delayed and achieved after 6–24 h of
exposure. Thus, neither the presence of a high inoculum nor the
presence of rat serum significantly influenced the bactericidal
activity of daptomycin in vitro.
Amoxicillin (100 mg/L) produced a 3 log10 reduction in
colony counts at 24 h against susceptible E. faecalis JH2-2 and
E. faecalis JH2-2/pIP819 isolates. Against E. faecium D366,
amoxicillin reduced by 1.5 log10 cfu/mL the number of organisms
at 24 h. Vancomycin (40 mg/L) and teicoplanin (40 mg/L)
achieved 1.5 log10 cfu/mL reduction in bacterial counts at 24 h
for the susceptible E. faecalis JH2-2 strain. Against E. faecalis
JH2-2/pIP819 (VanA type) vancomycin and teicoplanin exhibited
no activity. Against E. faecium D366 (VanB type), vancomycin
exhibited no activity while teicoplanin was bacteriostatic after
24 h of incubation. The presence of 50% rat serum did not
significantly influence the activity of ampicillin and vancomycin,
but decreased or abolished that of teicoplanin (data not shown).
Pharmacokinetic and pharmacodynamic studies
The peak (Cmax) and trough serum concentrations (mean – SD
for 3–10 individual animals) of daptomycin in rat serum were,
respectively, 90.2 – 16.9 and 12.6 – 4.3 mg/L. The AUC was
771.2 mg·h/L and the half-life 8.5 h. These values for daptomycin
in rats were very close to the values reported in humans during
treatment with a daily dose of 6 mg/kg iv.14 Protein binding of
daptomycin in rat serum was 89.3% (–3.5%). This value was
similar to that reported for this drug (90%) in other rodents and in
humans.17,28 The peak and trough concentration (mean – SD for
3–13 individual animals) of amoxicillin (respectively, 122.1 –
31.6 and 7.6 – 4.6 mg/L), vancomycin (respectively, 37.9 – 5.5
and 6.1 – 4.7 mg/L) and teicoplanin (respectively, 54.0 – 21.7 and
5.3 – 1.4 mg/L) were comparable to the values reported for these
drugs in humans.14,25–27
Therapy of experimental endocarditis
Results of therapy are shown in Table 2. For the antimicrobial
susceptible strain E. faecalis JH2-2, all treatment arms showed
significant efficacy compared to that of untreated controls in
reducing both infection and bacterial counts in vegetations
(P < 0.05). Against the VanA-resistant E. faecalis JH2-2/
pIP819, daptomycin and amoxicillin showed similar activity in
sterilizing valves and reducing titres in vegetations compared to
controls (P < 0.001). Both regimens were significantly superior
to vancomycin (P < 0.001). Against the ampicillin-resistant
and VanB-resistant E. faecium D366, daptomycin was superior
(P < 0.005) to controls, amoxicillin and vancomycin in reducing
valve infection, and to either of the comparators (P < 0.05)
in lowering bacterial counts in vegetations. Daptomycin-non-
susceptible enterococci were not detected during the time period
evaluated. Amoxicillin significantly reduced bacterial titres in
vegetations compared with titres in controls (5.21 versus
7.29 log10 cfu/g; P < 0.001), but this drug did not sterilize any
cardiac vegetation. Teicoplanin allowed a significant reduction
(P < 0.05) of both valvular infection and bacterial counts when
compared to controls, amoxicillin and vancomycin. No change in
drug susceptibility was observed among any of the post-therapy
vegetation homogenate samples during the study period.
Discussion
The occurrence of multiple antibiotic resistance in enterococci
underscores the need for alternative therapies. This study high-
lighted the potent efficacy of daptomycin against susceptible and
Table 1. MICs of daptomycin, amoxicillin, vancomycin and









Daptomycin 1 1 2
Amoxicillin 0.25 0.25 4
Vancomycin 1 >64 >64
Teicoplanin 0.5 >64 0.12
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multidrug-resistant E. faecalis and E. faecium both in vitro and in
experimental endocarditis in rats. Similar to a previous report,29 in
our study daptomycin was rapidly bactericidal (within 2 h) for
enterococci in time–kill studies at clinically achievable concen-
trations (85 mg/L) obtained with a dose of 6 mg/kg once daily.
The rate of daptomycin killing was not affected by inoculum
density (106 or 108 cfu/mL). Yet, in accordance with previous
studies,30 despite its high protein binding (approximately 90%)
daptomycin did not lose its bactericidal activity in the presence
of rat serum, although a delayed killing was observed. In rats
with experimental endocarditis, simulated human kinetics of
6 mg/kg of daptomycin every 24 h, sterilized 82–91% of infected
MHB
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Figure 1. Killing curves of enterococci by daptomycin at a concentration of 85 mg/L simulating total (MHB) and free (MHB + 50% rat serum) antibiotic level
achieved at peak in rat or human serum. Killing experiments were performed at moderate (a) or high (b) inoculum densities. Data represent the mean – SD of two
to three independent experiments. The lower limit of detection was 1 log10 cfu/mL. Filled circles, E. faecalis JH2-2; filled triangles, E. faecalis JH2-2/pIP819;
filled squares, E. faecium D366. Open symbols represent growth of control bacteria.
Table 2. Therapeutic results of experimental endocarditis due to vancomycin-susceptible E. faecalis JH2-2, vancomycin-resistant
E. faecalis JH2-2/pIP819 (VanA type) and E. faecium D366 (VanB type)
Infected vegetation/total (mean – SD log10 cfu/g)
Regimen E. faecalis JH2-2 E. faecalis JH2-2/pIP819 E. faecium D366
Controls 11/11 (7.48 – 0.73) 9/9 (7.57 – 0.79) 12/12 (7.29 – 0.83)
Daptomycin 2/12* (2.32 – 0.56)*,† 2/11*,z (2.47 – 0.53)*,z 1/12*,z,# (2.11 – 0.38)*,†,z,#
Amoxicillin 1/9* (2.49 – 1.16)*,† 2/11*,z (2.28 – 0.55)*,z 9/9 (5.21 – 1.04)*,z
Vancomycin 4/9* (3.25 – 1.16)* 6/6 (8.27 – 0.51) 6/6 (7.90 – 0.29)
Teicoplanin 5/9* (4.41 – 2.52)* ND 4/9*,#,z (3.61 – 1.77)*,z,#
ND, not done.
The incidences of valve infection of the various groups were compared by Fisher’s exact test, and the bacterial counts in vegetations by the one-way analysis of
variance. Bonferroni correction for multiple comparison groups was applied.
*P < 0.05 versus controls.
†P < 0.05 versus teicoplanin.
zP < 0.05 versus vancomycin.
#P < 0.05 versus amoxicillin.
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vegetations, regardless of the ampicillin or vancomycin resistance
of the tested enterococci. Against ampicillin- and glycopeptide-
susceptible isolates daptomycin was as effective as amoxicillin or
vancomycin, but more active than teicoplanin. The greater
activity of daptomycin over teicoplanin could be explained in
part by its homogeneous pattern of distribution into cardiac
vegetations13 in contrast to the well-known poor diffusion ability
of teicoplanin.31 Both daptomycin and teicoplanin showed an
elevated protein binding, a factor that may be responsible for the
poor ability of antibiotics to penetrate into the core of the
vegetations and for antimicrobial failure in the therapy of
endocarditis.32–34 The antibacterial efficacy of daptomycin in
cardiac vegetations, together with the minimal effect of rat serum
in time–kill studies, suggest that a detrimental effect of the protein
binding of daptomycin could be marginal in the presence of high
serum concentration. On the other hand, daptomycin was
significantly more effective than all the three comparators against
the ampicillin- and vancomycin-resistant isolates. The success of
daptomycin in our study stands in contrast to the results of some
previously published animal models of enterococcal endocarditis
using daptomycin, where the drug demonstrated limited activ-
ity.12,13 Several differences in the design of the studies could
account for these contradictory results. First, in our study, the
animals were challenged with 10- to 100-times lower inoculum
(106 or 107 cfu) than in previous studies (108 cfu). Second,
treatment was started earlier in our study, i.e. 16 h versus 24 h12 or
72 h.13 In earlier studies, the use of a higher inoculum could
result in a greater starting bacterial density in vegetations, and
the delayed therapy after infection could allow bacteria to reach
the stationary phase of growth,35,36 both events eventually making
eradication by daptomycin more difficult.37 However, these
differences are unlikely to be responsible for the divergent results
with our study for the following reasons: (i) colony counts at the
onset of therapy were not very different in previous studies (8.0
log10 cfu/g) and in our study (7.3–7.6 log10 cfu/g); (ii) the
bactericidal activity of daptomycin was shown to be reduced only
slightly by an increasing inoculum density38 (this study) and (iii)
the killing activity of daptomycin is maintained in the stationary
phase of growth.39 The better results of this study are most
probably explained by the fact that we simulated in rat serum the
whole human kinetics attained by a dose of 6 mg/kg once daily,14
the daptomycin regimen currently being considered for human
use. This regimen afforded daptomycin peak serum levels 1.5–2
times higher than those used by Bush et al.12 and Caron et al.13 Its
efficacy is in line with the concentration-dependent activity of
daptomycin.40 Moreover, the simulation of the whole human
kinetics of the drug matched not only the peak drug concentration
but also the subsequent elimination, in contrast to prior studies
that have not taken into account the shorter half-life of most drugs
in small animals than in humans. As an example, the half-life
of daptomycin in Bush’s study,12 who reproduced peak levels
in rabbit serum close to those achieved in human serum by a
regimen of 4 mg/kg, was of 5.8 h compared with 7.4–8.1 h in
humans.14 In contrast, in our work the half-life in rats (8.5 h)
closely mimicked that in humans (7.8–8.9 h).14 The use of lower
peak serum levels and shorter half-life could result in failure due
to inferior unbound levels of daptomycin in serum12,13 and/or
regrowth of the bacteria, as demonstrated in an in vitro
pharmacodynamic model by Cha et al.40 with doses smaller
than 6 mg/kg/day. On the other hand, the data presented here
confirmed the effectiveness of daptomycin against enterococcal
endocarditis in rabbits when similar serum levels of the drug were
used.41 In addition, our results are consistent with more recent
findings by Akins and Rybak42 and Cha and Rybak43 in an
in vitro model of simulated endocardiac vegetations. Indeed, these
authors demonstrated daptomycin efficacy against vancomycin-
resistant E. faecium by simulating the kinetics of the drug at
6 mg/kg/day. Studies in neutropenic mouse thigh infection models
have shown that the best predictor of in vivo efficacy of
daptomycin against Staphylococcus aureus and enterococcal
infections was either the AUC/MIC ratio or the Cmax/MIC
ratio.16,17,44 In animals infected with S. aureus, Safdar et al.44
reported that total AUC/MIC ratios of 388–537 or a free AUC/
MIC ratio of 42 were correlated with successful daptomycin
outcome. In the same study, total Cmax/MIC ratios of 59–94 were
also correlated with efficacy. Louie et al.17 on the other hand,
suggested that a total AUC/MIC ratio of 516.5 was required to
achieve 80% killing. For Dandekar et al.16 using enterococci as
the infectious organism, the 80% effectiveness was associated
with free AUC/MIC ratios of 15–32. In our study, efficacy (>80%
cure) of daptomycin against enterococcal endocarditis in rats
was provided by pharmacodynamic values similar to those that
predicted daptomycin efficacy in murine thigh infection models,
i.e. total AUC/MIC ratios of 386–771, free AUC/MIC ratios of
42–84, total Cmax/MIC ratios of 45–90 and free Cmax/MIC ratios
of 5–10. Based on the use of daptomycin human kinetics and
given that serum protein binding of this compound was shown to
be comparable in rodents and in humans (ca. 90%)17,28 such
pharmacodynamic values should anticipate daptomycin efficacy
against severe bacterial infections in humans. In summary, we
demonstrated that daptomycin, at doses mimicking human
kinetics of 6 mg/kg iv once a day, was effective in rats with
enterococcal endocarditis whatever the phenotype of resistance to
ampicillin and glycopeptides of the strains. This dose was recently
shown to be as effective as standard therapy for treatment of
S. aureus infective endocarditis in humans.45 Collectively, these
data indicate that 6 mg/kg iv once a day daptomycin would seem
to be an appropriate treatment for patients who have serious
enterococcal infections. Skeletal muscle toxicity was the principal
concern regarding the safety of daptomycin in past studies.7 Thus,
although the use of once-daily administration optimizes dapto-
mycin safety compared to multiple dose regimens,18 it should be
interesting to monitor symptoms of muscle damage in patients
treated with 6 mg/kg/day, as clinical safety data using this
regimen are scarce.
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